Dana H. Simmons

Dana H. Simmons

Auto-generated profile, based on publicly available information

Dana H. Simmons

Department of Neurobiology, University of Chicago, Chicago, Illinois 60637, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPClaire Piochon
Claire Piochon
AKAlexander D. Kloth
Alexander D. Kloth
GGGiorgio Grasselli
Giorgio Grasselli
HTHeather K. Titley
Heather K. Titley
HNHisako Nakayama
Hisako Nakayama
CHChristian Hansel
Christian Hansel
A common feature of autism spectrum disorder (ASD) is the impairment of motor control and learning, occurring in a majority of children with autism, consistent with perturbation in cerebellar function. Here we report alterations in motor behaviour and cerebellar synaptic plasticity in a mouse model (patDp/+) for the human 15q11-13 duplication, one of the most frequently observed genetic aberrations in autism. These mice show ASD-resembling social behaviour deficits. We find that in patDp/+ mice delay eyeblink conditioning—a form of cerebellum-dependent motor learning—is impaired, and observe deregulation of a putative cellular mechanism for motor learning, long-term depression (LTD) at parallel fibre-Purkinje cell synapses. Moreover, developmental elimination of surplus climbing fibres—a model for activity-dependent synaptic pruning—is impaired. These findings point to deficits in synaptic plasticity and pruning as potential causes for motor problems and abnormal circuit development in autism.

31 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CPClaire Piochon
Claire Piochon
HTHeather K. Titley
Heather K. Titley
DSDana H. Simmons
Dana H. Simmons
GGGiorgio Grasselli
Giorgio Grasselli
YEYpe Elgersma
Ype Elgersma
CHChristian Hansel
Christian Hansel
Significance: Instructive signals play an important role in synaptic plasticity and learning. For example, at cerebellar parallel fiber (PF)-Purkinje cell synapses, climbing fiber (CF) coactivation provides an instructive signal that promotes long-term depression (LTD) by amplifying spine calcium transients above a threshold level that, at these synapses, is higher than for LTP induction. Here, we show that the CF instructive signal maintains its control over PF plasticity regardless of the PF synaptic activation frequency, which, on its own, alters spine calcium signaling. We demonstrate that high-frequency stimulation reduces the calcium sensitivity of LTD, resulting from inhibitory calcium/calmodulin-dependent kinase II autophosphorylation at Thr305/306. We propose that this regulatory mechanism causes a horizontal shift of the long-term potentiation/LTD cross-over point, making plasticity independent from absolute calcium amplitudes.

23 November 2023 in Expert Opinion on Biological Therapy
Verified
Journal Article
Open access
TSTro Sekayan
Tro Sekayan
DSDana H. Simmons
Dana H. Simmons
ADAnnette von Drygalski
Annette von Drygalski
Congenital hemophilia B (HB) is an X-linked bleeding disorder resulting in Factor IX (FIX) deficiency and bleeding of variable severity. There is no cure for HB. Typical management consists of prophylactic intravenous (IV) recombinant or plasma-derived FIX infusions. Etranacogene dezaparvovec-drlb (Hemgenix, AMT-061) is an adeno-associated virus serotype 5 (AAV5) vector containing a codon-optimized Padua variant of the human F9 gene with a liver-specific promoter. Etranacogene dezaparvovec-drlb received FDA approval on 22 November 2022 for the treatment of HB in adult patients who use FIX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have experienced repeated, serious spontaneous bleeding episodes. This drug profile discusses the safety and efficacy of etranacogene dezaparvovec-drlb in patients with HB. Etranacogene dezaparvovec-drlb therapy results in stable and sustained expression of near-normal to normal FIX levels in patients with HB regardless of neutralizing antibodies to AAV5 up to a titer of 678. Use led to significant reduction in bleeding and FIX prophylaxis. Etranacogene dezaparvovec-drlb was well tolerated; however, 17% of patients required corticosteroid therapy for alanine aminotransferase (ALT) elevation. Etranacogene dezaparvovec-drlb therapy marks the beginning of an exciting era in HB treatment and opens questions regarding treatment longevity and long-term safety.

17 November 2014 in Learning & Memory
Verified
Journal Article
Open access
PDF file
BBBoeke J. van Beugen
Boeke J. van Beugen
XQXin Qiao
Xin Qiao
DSDana H. Simmons
Dana H. Simmons
CZChris I. De Zeeuw
Chris I. De Zeeuw
CHChristian Hansel
Christian Hansel
Ampakines are allosteric modulators of AMPA receptors that facilitate hippocampal long-term potentiation (LTP) and learning, and have been considered for the treatment of cognition and memory deficits. Here, we show that the ampakine CX546 raises the amplitude and slows the decay time of excitatory postsynaptic currents (EPSCs) at cerebellar parallel fiber (PF) to Purkinje cell synapses, thus resembling CX546 effects described at hippocampal synapses. Using the fluorescent calcium indicator dye Oregon Green BAPTA-2 and an ultra-high-speed CCD camera, we also monitored calcium transients in Purkinje cell dendrites. In the presence of CX546 in the bath, PF-evoked calcium transients were enhanced and prolonged, suggesting that CX546 not only enhances synaptic transmission, but also boosts dendritic calcium signaling at cerebellar synapses. In contrast to previous observations in the hippocampus, however, CX546 applied during cerebellar recordings facilitates long-term depression (LTD) rather than LTP at PF synapses. These findings show that ampakines selectively modify the LTP–LTD balance depending on the brain area and type of synapse, and may provide tools for the targeted regulation of synaptic memories.

25 July 2023 in BioDrugs
Verified
Journal Article
Open access
PDF file
CTCourtney D. Thornburg
Courtney D. Thornburg
DSDana H. Simmons
Dana H. Simmons
ADAnnette von Drygalski
Annette von Drygalski
Hemophilia is characterized by a deficiency in coagulation factors VIII or IX. The general standard of care for severe hemophilia is frequent intravenous recombinant or plasma-derived factor replacement to prevent bleeding. While this treatment is effective in preventing bleeding, frequent infusions are burdensome for patients. Nonadherence to the therapeutic regimen leaves people with hemophilia at risk for spontaneous and traumatic bleeds into joints as well as life-threatening bleeds such as intracranial hemorrhage. The chronicity of the disorder often leads to the formation of target joints, causing long-term pain and impairing mobility. As a monogenic disorder with well-understood genetics, hemophilia is an ideal disorder for implementing innovations in gene therapies. Indeed, recent approvals of two gene therapy products have the potential to shift the hemophilia treatment paradigm. Valoctocogene roxaparvovec and etranacogene dezaparvovec-drlb are gene therapies for hemophilia A and B, respectively. These therapies, given as a single intravenous infusion, may improve patients’ quality of life, decreasing treatment burden and resulting in factor expression that virtually eliminates the need for factor replacement. Since both treatments involve viral vectors targeted to the liver, short- and long-term safety and efficacy monitoring involves monitoring liver enzymes to track liver health. Long-term monitoring of efficacy, durability of gene expression, and safety are ongoing. Gene therapy presents a promising new therapeutic option for patients with hemophilia and warrants continued innovation and investigation.